 Provider News GeorgiaOctober 2023 Provider Newsletter Contents
GABCBS-CRCM-038798-23-CPN38706 Carelon Behavioral Health, Inc. is an independent company providing utilization management services on behalf of the health plan. Beginning with claims processed on and after November 15, 2023, we will update our claims editing process for outpatient facility claims by applying the Medicare National Correct Coding Initiative (NCCI) Medically Unlikely Edits. NCCI edits are Centers for Medicare & Medicaid Services (CMS) developed guidelines to promote national correct coding based on industry standards for current coding practices. These edits provide an opportunity to shift certain existing back-end reviews to front-end adjudication for outpatient facility claims. While this may facilitate quicker claim adjudication, it may also cause claims to deny frequency unit limits tied to Medically Unlikely Edits (MUEs) if correct coding guidelines are not followed. For additional information, please visit CMS.gov and select the Medically Unlikely Edits page. If you have questions about this communication or need assistance with any other item, contact your Provider Relationship Management representative. MULTI-BCBS-CM-036615-23-CPN36574 The Consolidated Appropriations Act (CAA) of 2021 contains a provision that requires online provider directory information be reviewed and updated as needed at least every 90 days. Maintaining your online provider directory information is essential for members and healthcare partners to connect with you when needed. Please review your information frequently and let us know if any of your information we show in our online directory has changed. Submit updates and corrections to your directory information by following the instructions on our Provider Maintenance web page. Online update options include: - Add/change an address location.
- Name change.
- Provider leaving a group or a single location.
- Phone/fax number changes.
- Closing a practice location.
Reviewing your information helps us ensure your online provider directory information is current. Through genuine collaboration, we can simplify access to care and help you deliver high-quality, equitable healthcare. MULTI-BCBS-CM-038049-23-SRS38044 Having reliable internet access is an important part of life. The internet helps us find information and connect with people, including finding and connecting with healthcare providers via virtual visits. However, not everyone can afford it. We share a health vision with our care provider partners that means real change for consumers. Making the internet more accessible is one way we can improve the whole health of our communities. The Affordable Connectivity Program can help. What is the Affordable Connectivity Program?The Affordable Connectivity Program is a government program that helps families who may need assistance pay for internet access. Qualified households can receive: Who is eligible for the program?A household is eligible for the Affordable Connectivity Program if: - Participates in certain government assistance programs such as the Supplemental Nutrition Assistance Program (SNAP), Medicaid, Social Security Income (SSI), the Free and Reduced-Price School Lunch Program or School Breakfast Program, or others.
- Participates in certain Tribal assistance programs, such as Head Start, Tribal Temporary Assistance for Needy Families (TANF), or others.
- Received a Federal Pell Grant during the current award year.
- Already receives a Lifeline benefit (another government program providing discounts on internet and phone service).
How do my patients apply?Your eligible patients can apply for the Affordable Connectivity Program online or by mail. They can also ask their current internet provider if they participate in the program. Please direct your patients to learn more at AffordableConnectivity.gov. MULTI-BCBS-CRCM-036097-23-CPN34208 We know one of the reasons you call us for claims status is because all the information you need isn’t always available. We want to change that by making Availity Essentials’* claims status enhancements available for Anthem member inquiries. In November, enjoy the benefits of expanded search options, filters, and downloadable reports from the same Claims Status application you are using for other payers on Availity.com. Claims Status application enhancements include: - Improved search options (by patient account number and claim number).
- Customizable fields with sort options and exportable results.
- Details screen that includes interest and payment information.
- Remit Viewer (Electronic Remittance Advice — 835).
- Simplified layout that includes less scrolling and screens.
Enhancements will be rolled out, maximizing the effectiveness of the application. These updates are also available for claims submitted through clearinghouses or care providers using API transmissions. The new claim status enhancements are in addition to the benefits you already enjoy: - Submit documentation directly to your claim
- File a claim dispute
- Verify eligibility and benefits
- Send a secure message or chat with us directly from the application
- Chat with Payer available in all markets
Training and supportLearn how to optimize your experience using the Claims Status application on Availity.com by attending live or recorded webinar sessions. Visit the learning microsite here and register for training today. Enhancing claims status results is one of the ways Anthem is collaborating for success. For questions or additional information, reach out to your Provider Relations Account Management Representative or use Chat with Payer. * Availity, LLC is an independent company providing administrative support services on behalf of the health plan. MULTI-BCBS-CDCRCM-034719-23-CPN34127 Background:We continue to focus and expand our consumer tools and content to assist members in making more informed and personalized healthcare decisions. Provider performance can vary widely in relation to efficiency, quality, and member experience. Our goal as your Medicare health plan partner is to ensure our members receive high-quality care that leads to improved member health outcomes across a wide range of variables. Beginning January 1, 2023, we added a new sorting option on the FindCare tool for members to leverage when they are searching for a primary care provider. This sorting option, called Personalized Match Phase 1, is based on each provider’s score relative to their peers in the patient’s preferred mileage search radius. Providers are listed in order of their total score, though no individual scores appear within the tool or be visible to Medicare covered patients. The Personalized Match Phase 1 algorithm is based on quality and efficiency criteria to assist members in making more informed choices about their medical care. Other sorting options are still available on FindCare for our members. Personalized Match Phase 1 highlights:- We strive to make healthcare simpler, more affordable, and more accessible, and one of the ways to help achieve that goal is to ensure that consumers are connected with care providers who have strong track records delivering quality care.
- Beginning on November 10, 2023, we will upgrade the online FindCare tool for Medicare members with a new sorting option called Personalized Match Phase 1, to match consumers with providers who perform well in efficiency and quality metrics within a certain geographical distance.
- The new sorting option, known as Personalized Match Phase 1, will be the default for consumers who search for Medicare non-primary specialty care providers in FindCare.
- We currently offer Personalized Match to Commercial consumer members. Personalized Match seeks to match consumers with documented health conditions with provider ranked based on cost effectively managing quality care. For example, if a consumer who has been given a diagnosis of diabetes conducts a search, they will be matched with providers whose patients are more likely to cost effectively manage similar patients with diabetes (for example, consistently receive recommended A1c tests A consumer who is a 60-year-old male would receive different Personalized Match provider rank order than a consumer who is a 30-year-old female). The goal is to move to this full Personalized Match solution in Medicare in the future. Personalized Match Phase 1 only analyzes providers’ quality and efficiency performance regardless of member characteristics for generating the sort order.
- You may review a copy of the new sorting methodology which has been posted on Availity.*
- If you have general questions regarding this new sorting option, please submit an inquiry via the web on Availity.
- If you would like information about your scoring used for this sorting option or if you would like to request reconsideration of your score, you may do so by submitting an inquiry via the web on Availity.
- This change is part of a greater effort to help improve access to high quality, affordable healthcare, which is essential to our customers.
FAQWhy are we reimagining the strategy for evaluating non-primary specialty care providers? There is variability in provider performance (efficiency, quality, experience), and we want to ensure all members receive high-quality care that leads to improved patient outcomes. The strategy aligns with the future direction of our specialty provider care strategy. This phase of the Medicare FindCare improvement utilizes measures related to appropriate practice (for example, overuse and underuse measures). We utilize a vendor, Motive Medical, to generate an overall Appropriate Practice Score at the NPI level, based on all CMS Fee-for-Service members. How will I know my inquiry went through successfully once I submit? An email will be sent to the inquirer acknowledging receipt of inquiry within two business days. What is the turnaround time from when I submit my question to receiving an answer? The goal is to have all questions answered within two business days. If further clarification is needed, or if detailed research is required, that time frame will be extended. How will I receive my response? An email will be sent with the required information back to the email address provided during the initial inquiry request. How do I submit an inquiry? Inquiries can be made at Availity site. There are three dropdown options for inquiry types. These are: 1) General Program Inquires, 2) Request a Copy of Your Provider Performance Scorecard, and 3) Provider Performance Scorecard Inquiries. An open text field is available to describe the nature of the inquiry in more detail. What type of inquiries can I submit? Any questions relating to Personalized Match Phase 1 that is not answered in this FAQ or by the Methodology document. Do providers have any recourse if they feel their Provider Performance Scorecard is inaccurate? If a provider disagrees with their Provider Performance Scorecard results, the provider can submit an inquiry at Availity site detailing their reasoning. We will determine the best course of action as needed, but potential outcomes could be a provider consultation, reanalysis, and potentially a rescoring of provider performance to be reflected in Personalized Match Phase 1 and the Provider Performance Scorecard. What provider specialties are included in Personalized Match Phase 1? For 2023, selected non-primary specialty care providers are included. We plan to potentially incorporate other provider specialties in future provider performance evaluations. What measures are included in quality scoring and why were they included? The quality measures selected for Personalized Match Phase 1 include underuse and overuse measures, within the appropriate practice domain. Measures vary by specialty and are available on request. How are measures weighted? Motive Medical considers three factors in weighting the importance of each measure as it impacts the overall NPI Appropriate Practice Score (APS): - Measure volume (for example, the number of instances a provider is eligible for measurement)
- Cost differential (for example, the difference in cost between the inappropriate service chosen versus the cost of the appropriate alternative), and
- Patient harm (for example, measures weigh more heavily if they have a stronger negative impact on the patient).
What measurement year and source are used in quality scoring? Motive Medical’s Fall 2022 Refresh was used for quality scoring with varying claim periods by measure including dates from January 1, 2019, to December 31, 2021. What are the inclusion criteria for quality scoring? A non-primary specialist care provider must have at least three appropriateness measures with at least ten members in each measure (a few measures require 20 members) for the APS score to be calculated. If the provider does not meet this threshold, the APS score is not available. The APS score can be described in the following steps: - Within each specialty, calculate the mean Motive Medical APS score to be used as the national-specialty benchmark.
- For each non-primary care specialty provider, calculate an APS Observed to Expected (O/E) ratio, comparing the provider to the benchmark for the same specialty:
- Provider’s APS / national-specialty benchmark.
- The quality score is the provider’s APS O/E percentile ranking at the national-specialty level.
What factors go into your efficiency target? The factors going into our efficiency target are the episodes of the members are assigned to provider specialty who has the highest cost within the episode for Surgery and Evaluation costs. The observed cost of an episode is the sum of provider’s total allowed costs. The expected or peer benchmark cost of an episode is the average cost of treating the same condition or procedure with the same severity level for all specialists in the same line of business, specialty and geographic area multiplied by number of provider’s volume. For ETGs the measure is at the condition level (diabetes, asthma) and for PEGs it’s the procedure level (knee replacement, lumbar fusions): - Observed cost: Total provider cost
- Expected cost: Specialty average cost for same case mix * physician volume
- Efficiency index = observed / expected
How is your efficiency target set? Efficiency scores from the condition ETG and PEG procedure (observed/expected ratio scores) are blended into one final efficiency score by weighing the percentage of all the dollars that are tied to procedures vs conditions. This ensures that the efficiency scores for proceduralists (surgeons) are based more heavily on the procedure episodes. This is the final blended efficiency score for the provider: - A minimum of 20 episodes that have benchmarks are required to calculate a condition efficiency or procedure efficiency score for the provider.
- A 90% statistical confidence interval is computed around the provider’s final blended efficiency score to account for the level of statistical uncertainty around the point estimation. For example, a provider with a final blended efficiency score of 0.97 might have the following confidence interval: Upper confidence level (UCL) of 1.03, Lower Confidence level (LCL) of 0.91.
Cost ratings are then assigned to providers and provider groups using confidence intervals, as shown below. The provider group cost ratings are used for TIN Designation while individual provider cost ratings are used for the Provider composite score. 
For high-cost cases, how do you normalize which can occur across different groups? We exclude outlier episodes from the scoring, low cost and high-cost episodes are flagged by the software at Condition/Procedure, Severity, and Line of business level. Provider specialties with quality measures:- Cardiac electrophysiology
- Cardiac surgery
- Cardiology
- Colorectal surgery
- Endocrinology
- Gastroenterology
- General surgery
- Geriatric psychiatry
- Hand surgery
- Hematology
- Hematology/oncology
- Interventional cardiology
- Medical oncology
- Nephrology
| - Neurology
- Neurosurgery
- Obstetrics gynecology
- Ophthalmology
- Orthopedic surgery
- Otolaryngology
- Psychiatry
- Pulmonary disease
- Radiation oncology
- Rheumatology
- Surgical oncology
- Thoracic surgery
- Urology
- Vascular surgery
|
* Availity, LLC is an independent company providing administrative support services on behalf of the health plan. MULTI-BCBS-CR-032328-23-CPN32306 Find Care, the doctor finder and transparency tool in the Anthem Blue Cross and Blue Shield (Anthem) online directory, provides Anthem members with the ability to search for in-network providers using the secure member website. This tool currently offers multiple sorting options, such as sorting providers based on distance, alphabetical order, and provider name. Beginning in the second quarter of 2024 or later, an additional sorting option will be available for our Medicare Advantage members to search by provider performance called Personalized Match Phase 1. This sorting option is based on provider efficiency and quality outcomes, alongside member search radius. Providers with the highest overall ranking within the member’s search radius will be displayed first. Members will continue to have the ability to sort based on distance, alphabetical order, and provider name: - You may review a copy of the Personalized Match Phase 1 methodology that has been posted on Availity* – our secure Web-based provider tool – using the following navigation: Go to Availity > Payer Spaces > Health Plan > Education & Reference Center > Administrative Support > Personalized Match Phase 1 Methodology.pdf.
- If you have general questions regarding this new sorting option, please submit an inquiry via the web at Availity.
- If you would like information about your quality or efficiency scoring used as part of this sorting option or if you would like to request reconsideration of those scores, you may do so by submitting an inquiry to Availity.
Anthem has expanded the scope of Personalized Match Phase 1 to include selected specialty providers and will continue to focus and expand our consumer tools and content to assist members in making more informed and personalized healthcare decisions. * Availity, LLC is an independent company providing administrative support serviceson behalf of the health plan. MULTI-BCBS-CR-032115-23-CPN27574 Fifty-three million Americans (more than one in five) are family caregivers. According to a new study, Caregiving in the U.S. 2020, caregivers face health challenges of their own. Nearly a quarter of caregivers find it hard to take care of their own health and say that caregiving has made their own health worse. Now, helpforcancercaregivers.org is here to help caregivers care for themselves. This interactive website, available 24/7, provides the information and resources that caregivers need to care for their own health and well-being. The website walks users through a brief survey and then provides a personalized Self-Care Guide to help them improve their health. Studies show that family caregivers suffer from poorer physical health than those who do not have additional caregiving responsibilities. Studies have also found that: - Caregivers show higher levels of depression.
- Caregivers suffer from high levels of stress and frustration — which can lead to burnout.
- Stressful caregiving situations may lead to harmful behaviors, such as abusing drugs or alcohol.
- Caregivers have an increased risk of heart disease.
- Caregivers have lower levels of self-care.
- Chronic diseases of caregivers are often more difficult to manage.
- Caregivers have an increased risk of sickness and premature death.
Evidence has also shown that education and intervention reduce caregiver strain, uncertainty, and helplessness and that information helps normalize the caregiver experience and enhances a sense of control. Caregivers for your patients can access Help for Cancer Caregivers at helpforcancercaregivers.org. MULTI-BCBS-CM-036949-23-CPN36922 As a contracted provider for Special Needs Plan (SNP) from Anthem Blue Cross and Blue Shield (Anthem), you are required to participate in an annual training on Model of Care for Anthem. This training includes a detailed overview of SNPs and program information — highlighting cost sharing, data sharing, participation in the Interdisciplinary Care team (ICT), where to access the member’s health risk assessment results, plan of care, and benefit coordination. Training for SNP product for Anthem is self-paced and available at availity.com.* The training must be completed by December 31, 2023. How to access the Custom Learning Center on the Availity website:- Log in to Availity website at availity.com.
- At the top of Availity website, select Payer Spaces and select the appropriate payer.
- On the Payer Spaces landing page, select Access Your Custom Learning Center from Applications.
- In the Custom Learning Center, select Required Training.
- Select Special Needs Plan and Model of Care Overview.
- Select Enroll.
- Select Start.
- Once the course is completed, select Begin Attestation and complete.
Not registered for Availity Essentials?Have your organization’s designated administrator register your organization for the Availity website: - Visit availity.com to register.
- Select Register.
- Select your organization type.
- In the Registration wizard, follow the prompts to complete the registration for your organization.
Refer to these PDF documents: https://apps.availity.com/availity/Demos/Registration/index.htm for complete registration instructions. * Availity, LLC is an independent company providing administrative support services on behalf of the health plan. MULTI-BCBS-CR-022628-23, CPN22400, MULTI-BCBS-CR-039458-23-CPN39408 This forum has moved from the original date of September 27, 2023 to October 19, 2023Register today for the youth mental health forum hosted by Anthem Blue Cross and Blue Shield (Anthem) and Motivo* for Anthem providers on October 19, 2023. Thursday, October 19, 2023 3:30 to 5 p.m. Eastern time This important event will address the critical need to engage young people in leading their mental health. By deepening the discussion on youth mental health, we can do our part to foster a culture of understanding and support for youth and young adults. Authentic conversations lead to reducing implicit bias and improving the health and wellbeing of all Americans and the communities in which we live and serve. Please join us to hear from a diverse panel of experienced professionals and young leaders as we explore the challenges experienced by today’s youth, amplify the experiences and ideas of young people, and equip attendees with practical tools and innovative approaches to create meaningful change. Each forum will continue the exploration of ways we can reduce disparities in healthcare, demonstrate cultural humility, address, and deconstruct bias, have difficult and productive conversations, learn about valuable resources, increase inclusion, advance equity in healthcare. Please register for this event by visiting this link. * Motivo is an independent company providing a virtual forum on behalf of the health plan. MULTI-BCBS-CRCM-039386-23-CPN39367 OverviewWe’re committed to being actively involved with our care provider partners and going beyond the contract to create a real impact on the health of our communities. That’s why we offer care providers free continuing medical education (CME) sessions to learn best practices to overcoming barriers in achieving clinical quality goals and improved patient outcomes. Engagement Hub objectives:- Learn strategies to help you and your care team improve your performance across a range of clinical areas.
- Apply the knowledge you gain from the webinars to improve your organization’s clinical quality.
- Offer care providers a convenient way to earn CME credits at a time that works best for them.
- Each session in this series is approved for one American Academy of Family Physicians credit:
- Browse the listing of free CME webinars.
- Open the CME webinars in Google Chrome
MULTI-BCBS-CRCM-038423-23-CPN38131 Medical drug benefit Clinical Criteria updates On August 19, 2022, September 12, 2022, November 18, 2022, February 24, 2023, May 19, 2023, June 12, 2023, and July 11, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross and Blue Shield (Anthem). These policies were developed, revised, or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. If you have questions or would like additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: - New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Please share this notice with other providers in your practice and office staff. Note: - The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Document number | Clinical Criteria title | New or revised | October 18, 2023 | *CC-0243 | Vyjuvek (beremagene geperpavec) | New | October 18, 2023 | *CC-0242 | Epkinly (epcoritamab-bysp) | New | October 18, 2023 | *CC-0241 | Elfabrio (pegunigalsidase alfa-iwxj) | New | October 18, 2023 | CC-0228 | Leqembi (lecanemab) | Revised | October 18, 2023 | *CC-0061 | Gonadotropin Releasing Hormone Analogs for the Treatment of Non-Oncologic Indications | Revised | October 18, 2023 | *CC-0015 | Infertility and HCG Agents | Revised | October 18, 2023 | *CC-0062 | Tumor Necrosis Factor Antagonists | Revised | October 18, 2023 | CC-0151 | Yescarta (axicabtagene ciloleucel) | Revised | October 18, 2023 | *CC-0177 | Zilretta (triamcinolone acetonide extended-release) | Revised | October 18, 2023 | CC-0149 | Select Clotting Agents for Bleeding Disorders | Revised | October 18, 2023 | CC-0032 | Botulinum Toxin | Revised | October 18, 2023 | *CC-0002 | Colony Stimulating Factor Agents | Revised | October 18, 2023 | *CC-0001 | Erythropoiesis Stimulating Agents | Revised | October 18, 2023 | *CC-0174 | Kesimpta (ofatumumab) | Revised | October 18, 2023 | *CC-0209 | Leqvio (inclisiran) | Revised | October 18, 2023 | *CC-0011 | Ocrevus (ocrelizumab) | Revised | October 18, 2023 | *CC-0005 | Hyaluronan Injections - Medicare Only | Revised |
MULTI-BCBS-CR-036939-23-CPN36113 Effective December 30, 2023, Anthem Blue Cross and Blue Shield (Anthem) will transition the Clinical Criteria for site of care reviews to the following Carelon Medical Benefits Management* (Caralon) site of care guidelines to perform medical necessity and clinical appropriateness reviews for the requested site of care for certain procedures. Program | Services | Carelon Guideline | CPT® code list links | Surgical | Routine outpatient surgical procedures across the following specialty services: gastroenterology (including upper and lower endoscopy), ophthalmology (such as cataract surgery), gynecology, dermatology, urology, pulmonary and musculoskeletal | Surgical Appropriate Use Criteria: Site of Service | https://tinyurl.com/8bruffkj | Radiology | Routine outpatient CT and MRI imaging such as head, chest, and extremity imaging. | Advanced Imaging Appropriate Use Criteria: Site of Care | https://tinyurl.com/y45hsv5h | Musculoskeletal | Select musculoskeletal and pain procedures, including shoulder and knee arthroscopies and epidural injections. | Surgical Appropriate Use Criteria: Site of Care | https://tinyurl.com/3xujthte | Rehabilitative Services | Routine outpatient speech, occupational, and physical therapy services | Outpatient Rehabilitative and Habilitative Services Appropriate Use Criteria: Site of Care | https://tinyurl.com/5dz92sp4 |
Note: These reviews do not apply to procedures performed on an emergent basis. Carelon Medical Benefits Management also manages the musculoskeletal level of care review using The Carelon Musculoskeletal Appropriate Use Criteria: Level of Care for Musculoskeletal Surgery and Procedures guideline. Members included in the programThe new review criteria apply to all Anthem members currently participating in the above mentioned Carelon Medical Benefits Management programs. To determine if prior authorization by Carelon Medical Benefits Management is required for a member, contact the Provider Services phone number on the back of the member’s ID card. The following members are excluded: Medicare Advantage (individual and group), Medicare, Medicare supplement, and the Federal Employee Program® (FEP). Prior authorization requirementsPrior authorization requirements remain the same. For services scheduled to begin on or after December 29, 2023, care providers must contact Carelon Medical Benefits Management to obtain prior authorization. Requested services received on or after December 29, 2023, will be reviewed with the new Clinical Criteria. Care providers may submit prior authorization requests to Carelon Medical Benefits Management at providerportal.com. Initiating a request and entering all the requested clinical information will provide an immediate determination 24/7. For questions related to guidelines, please contact Carelon Medical Benefits Management via email at MedicalBenefitsManagement.guidelines@Carelon.com. Additionally, you may download a copy of the current and upcoming guidelines here. * Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Anthem Blue Cross and Blue Shield is the trade name of Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-038847-23 The Medical Policy and Technology Assessment Committee adopted the attached new and/or revised Medical Policies and Clinical Guidelines. GABCBS-CM-038152-23 ATTACHMENTS (available on web): Medical Policy Updates (pdf - 0.51mb) The following services will be added to precertification for the effective dates listed below. Eligibility and benefits can be verified by accessing Availity Essentials* at Availity.com or by calling the number on the back of the member’s identification card. Service precertification is based on member’s benefit plan/eligibility at the time the service is reviewed/approved. Benefit plans vary widely and are subject to change based on the contract effective dates. The provider is responsible for verification of member eligibility and covered benefits. Except in the case of an emergency, failure to obtain precertification prior to rendering the designated services listed below may result in denial of reimbursement. Add to precertification | Criteria | Criteria description | Code | Effective date | DME.00032 | Automated External Defibrillators for Home Use | E0617 | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0260U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0264U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0265U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0266U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0267U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0268U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0269U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0270U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0271U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0272U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0273U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0274U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0276U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0277U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0278U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0332U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0335U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0336U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 0343U | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 81441 | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 81449 | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 81451 | 1/1/2024 | GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | 81456 | 1/1/2024 | GENE.00057 | Gene Expression Profiling for Idiopathic Pulmonary Fibrosis | 81554 | 1/1/2024 | LAB.00003 | In Vitro Chemosensitivity Assays and In Vitro Chemoresistance Assays | 0564T | 1/1/2024 | LAB.00003 | In Vitro Chemosensitivity Assays and In Vitro Chemoresistance Assays | 81535 | 1/1/2024 | LAB.00011 | Selected Protein Biomarker Algorithmic Assays | 0080U | 1/1/2024 | LAB.00011 | Selected Protein Biomarker Algorithmic Assays | 0247U | 1/1/2024 | LAB.00011 | Selected Protein Biomarker Algorithmic Assays | 0249U | 1/1/2024 | LAB.00011 | Selected Protein Biomarker Algorithmic Assays | 0360U | 1/1/2024 | LAB.00011 | Selected Protein Biomarker Algorithmic Assays | 81538 | 1/1/2024 | LAB.00015 | Detection of Circulating Tumor Cells | 0337U | 1/1/2024 | LAB.00015 | Detection of Circulating Tumor Cells | 0338U | 1/1/2024 | LAB.00019 | Proprietary Algorithms for Liver Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease | 0002M | 1/1/2024 | LAB.00019 | Proprietary Algorithms for Liver Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease | 0003M | 1/1/2024 | LAB.00019 | Proprietary Algorithms for Liver Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease | 0344U | 1/1/2024 | LAB.00019 | Proprietary Algorithms for Liver Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease | 81596 | 1/1/2024 | LAB.00024 | Immune Cell Function Assay | 86352 | 1/1/2024 | LAB.00027 | Selected Blood, Serum and Cellular Allergy and Toxicity Tests | 86343 | 1/1/2024 | LAB.00031 | Advanced Lipoprotein Testing | 0052U | 1/1/2024 | LAB.00033 | Protein Biomarkers for the Screening, Detection and Management of Prostate Cancer | 0228U | 1/1/2024 | LAB.00033 | Protein Biomarkers for the Screening, Detection and Management of Prostate Cancer | 0359U | 1/1/2024 | LAB.00035 | Multi-biomarker Disease Activity Blood Tests for Rheumatoid Arthritis | 81490 | 1/1/2024 | LAB.00036 | Multiplex Autoantigen Microarray Testing for Systemic Lupus Erythematosus | 0062U | 1/1/2024 | LAB.00037 | Serologic Testing for Biomarkers of Irritable Bowel Syndrome (IBS) | 0164U | 1/1/2024 | LAB.00037 | Serologic Testing for Biomarkers of Irritable Bowel Syndrome (IBS) | 0176U | 1/1/2024 | LAB.00041 | Machine Learning Derived Probability Score for Rapid Kidney Function Decline | 0105U | 1/1/2024 | LAB.00046 | Testing for Biochemical Markers for Alzheimer's Disease | 0346U | 1/1/2024 | LAB.00046 | Testing for Biochemical Markers for Alzheimer's Disease | 0358U | 1/1/2024 | LAB.00046 | Testing for Biochemical Markers for Alzheimer's Disease | 0361U | 1/1/2024 | LAB.00048 | Pain Management Biomarker Analysis | 0117U | 1/1/2024 | MED.00004 | Noninvasive Imaging Technologies for the Evaluation of Skin Lesions | 0658T | 1/1/2024 | MED.00004 | Noninvasive Imaging Technologies for the Evaluation of Skin Lesions | 96904 | 1/1/2024 |
* Availity, LLC is an independent company providing administrative support services on behalf of the health plan. GABCBS-CM-037997-23 Beginning with dates of service on or after January 1, 2024, the After-Hours, Emergency, and Miscellaneous E/M Services – Professional reimbursement policy will also apply to facility providers. The intent of this policy is to reimburse professional providers for rendering urgent services outside of regular hours (“after hours” services) when such services are: - Billed on a CMS-1500 form.
- Billed with an office place of service (POS 11).
- Rendered between 5:00 p.m. and 8:00 a.m. on weekdays or anytime on weekends based on arrival time and not the actual time the service commenced.
The policy will not allow separate reimbursement for “after hours” codes 99050 or 99051 when: - Billed by facility providers.
- Billed with POS 20 (urgent care facility).
The policy will be retitled After-Hours, Emergency, and Miscellaneous E/M Services – Professional and Facility. For specific policy details, visit anthem.com and select For Providers. Under the Provider Resources heading, select Policies, Guidelines & Manuals. On the next screen, select the Select a State. Next, under the Reimbursement Policies heading, select Access policies. MULTI-BCBS-CM-038560-23-CPN38439 New Reimbursement Policy
Genetic Tests: Once per Lifetime (Policy G-23002, effective 01/01/2024) Beginning with dates of service on or after January 1, 2024, Anthem Blue Cross and Blue Shield (Anthem) will implement a new reimbursement policy titled Genetic Tests: Once per Lifetime. This policy identifies specific genetic tests allowed once in a member’s lifetime. During the member’s lifetime, the germline genotype will not change. However, the interpretation of the gene sequence may change due to recategorization of variants, or other factors. Repeat sequencing is not required for future interpretation of germline genotype, or re-analysis of previously sequenced data. The Related Coding section includes a Once per Lifetime Genetic Test coding list, which describes the genetic procedures that are limited to once per lifetime sequencing. Reinterpretation of the original results are not separately reimbursable. For additional information, please review the Genetic Tests: Once per Lifetime reimbursement policy at https://www.anthem.com/medicareprovider. MULTI-BCBS-CR-033765-23-CPN29184 New Affordable Care Act (ACA) network AMGP Georgia Managed Care Company, Inc. is introducing a new network and set of Affordable Care Act (ACA)-compliant plans in mid-southern Georgia, beginning January 1, 2024. The new plans will utilize the Amerigroup provider network in specified counties and will be marketed as the Blue Value Individual Network HMO. Members who no longer qualify for Medicaid coverage or are not enrolled in any health benefit plan may find these products a more affordable coverage option. In 30 counties, Anthem will offer a $0 premium Silver plan with cost share reductions for individuals with the highest subsidy level. Types of individual health plans in GeorgiaSince the implementation of the ACA in 2014, Anthem has been offering ACA-compliant individual healthcare plans that can be purchased from healthcare.gov. Individual plans can also be purchased off the exchange from traditional sources such as a sales agent and anthem.com. In 2024, Anthem is offering ACA-compliant health plans statewide as outlined below. 

ReferralsThe new Blue Value Individual Network HMO plans will require that members have a PCP assigned who will coordinate their care. This PCP (or covering physician who shares the same TIN) will submit referrals to cover care from most specialists. More details about our referral process for these plans will be shared in an upcoming newsletter. Looking aheadWatch for more information about the new plans and network, including a quick reference guide, in upcoming newsletters. Additionally, we will be hosting several Blue Value Individual Network HMO provider sessions in November and December. Webinar dates and registration details will be announced later. Thank you for the quality care you continue to provide your patients, our members. We look forward to working together to achieve improved outcomes. GABCBS-CM-038066-23-SRS38066 Anthem Blue Cross and Blue Shield (Anthem) is excited to announce a new High Performing Provider (HPP) designation that will assign the designation HPP to care providers meeting certain cost and quality metrics. Through this new designation, Anthem is expanding our consumer tools and content to assist members in making more informed and personalized healthcare decisions. Initially, the designation will focus on certain types of professional providers, but it may be broadened to include other care provider types in the future. The High Performing Provider designation will launch on November 1, 2023. Anthem may highlight HPPs in various ways, including, but not limited to: - Special opportunities to participate, in product offerings.
- When members contact Anthem with requests for referral options.
- Placing a designation in Anthem’s Care and Cost Finder. This would be in addition to Anthem’s existing tool in Care and Cost Finder called Personalized Match that provides Anthem members with the option to search for in-network care providers through a specialized sorting tool that considers certain cost and quality metrics, as well.
For more information on the HPP designation, you can view the designation methodology or to know if your practice will receive the designation, send an email to HPPdesignation@elevancehealth.com. GABCBS-CM-037004-23-CPN36953 Specialty pharmacy updates for Anthem Blue Cross and Blue Shield (Anthem) are listed below. Prior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by Anthem’s medical specialty drug review team. Review of specialty pharmacy drugs for oncology use is managed by Carelon Medical Benefits Management, Inc.* Important to note: Currently, your patients may be receiving these medications without prior authorization. As of the effective date below, you may be required to request prior authorization review for your patients’ continued use of these medications. Including the National Drug Code (NDC) code on your claim will help expedite claim processing of drugs billed with a Not Otherwise Classified (NOC) code. Prior authorization updatesEffective for dates of service on and after January 1, 2024, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our prior authorization review process. Access our Clinical Criteria to view the complete information for these prior authorization updates. Clinical Criteria | Drug | HCPCS or CPT® code(s) | CC-0244* | Columvi (glofitamab-gxbm) | C9399, J3490, J3590, J9999 | CC-0245 | Izervay (avacincaptad pegol) | C9399, J3490, J3590, J9999 | CC-0246 | Rystiggo (rozanolixizumab-noli) | C9399, J3490, J3590, J9999 |
* Oncology use is managed by Carelon Medical Benefits Management. Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity. Step therapy updatesCourtesy notice — Effective for dates of service on and after October 1, 2023, updated step therapy criteria for iron agents found in the clinical criteria document for CC-0182 will be implemented. The preferred product list is being expanded to include Infed. Please refer to the clinical criteria document for details. Access our Clinical Criteria to view the complete information for these step therapy updates. Quantity limit updatesEffective for dates of service on and after January 1, 2024, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our quantity limit review process. Access our Clinical Criteria to view the complete information for these quantity limit updates. Clinical Criteria | Drug | HCPCS or CPT code(s) | CC-0245 | Izervay (avacincaptad pegol) | C9399, J3490, J3590, J9999 | CC-0246 | Rystiggo (rozanolixizumab-noli) | C9399, J3490, J3590, J9999 |
* Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. MULTI-BCBS-CM-038617-23-CPN38572 Anthem Blue Cross and Blue Shield expands specialty pharmacy precertification list The previous effective date was previously listed in error as October 1, 2023, this correct effective date is December 1, 2023. Effective for dates of service on and after December 1, 2023, the specialty Medicare Part B drugs listed in the table below will be included in our precertification review process. Federal and state law, as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions, take precedence over these precertification rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims. HCPCS or CPT® codes | Medicare Part B drugs | J9029 | Adstiladrin (nadofaragene firadenovec-vncg) | C9399, J7199 | Altuviiio (antihemophilic factor (recombinant) | C9399, J3490 | Lamzede (velmanase alfa-tycv) | J9350 | Lunsumio (mosunetuzumab-axgb) | J1440 | Rebyota (fecal microbiota, live – jslm) | J2502 | Signifor LAR (pasireotide) | C9151, C9399, J3490 | Syfovre (pegcetacoplan) | J9056 | Vivimusta (bendamustine) |
MULTI-BCBS-CR-023557-23-CPN23416 Expanded specialty pharmacy precertification list Effective for dates of service on and after January 1, 2024, the specialty Medicare Part B drugs listed in the table below will be included in our precertification review process. Federal and state law, as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions, take precedence over these precertification rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims. HCPCS or CPT® codes | Medicare Part B drugs | J3490, J3590 | Elfabrio (pegunigalsidase alfa-iwxj) | C9399, J3490, J3590, J9999 | Epkinly (epcoritamab-bysp) | J3490, J3590 | Qalsody (tofersen) | J3490, J3590 | Vyjuvek (beremagene geperpavec) | J9999 | Zynyz (retifanlimab-dlwr) |
MULTI-BCBS-CR-037831-23-CPN37401 |